Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS).

Nat Commun · 2026 · PMC12858947 · PMID 41530133

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

Further analysis of the cumulative TTF of EGFR TKI therapy revealed a strong trend suggesting that high MET expression was correlated with a shorter TTF 16 .

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.